UBE4A
Basic information
Region (hg38): 11:118359600-118399211
Links
Phenotypes
GenCC
Source:
- autosomal recessive non-syndromic intellectual disability (Supportive), mode of inheritance: AR
- multiple congenital anomalies/dysmorphic syndrome (Limited), mode of inheritance: AR
- neurodevelopmental disorder with hypotonia and gross motor and speech delay (Strong), mode of inheritance: AR
- neurodevelopmental disorder with hypotonia and gross motor and speech delay (Strong), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Neurodevelopmental disorder with hypotonia and gross motor and speech delay | AR | General | Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing | Craniofacial; Musculoskeletal; Neurologic; Ophthalmologic | 33420346 |
ClinVar
This is a list of variants' phenotypes submitted to
- Inborn_genetic_diseases (107 variants)
- not_provided (20 variants)
- Neurodevelopmental_disorder_with_hypotonia_and_gross_motor_and_speech_delay (5 variants)
- UBE4A-related_disorder (5 variants)
- not_specified (3 variants)
- Neurodevelopmental_disorder (1 variants)
- Retinitis_pigmentosa_11 (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the UBE4A gene is commonly pathogenic or not. These statistics are base on transcript: NM_001204077.2. Only rare variants are included in the table.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Effect | PathogenicP | Likely pathogenicLP | VUSVUS | Likely benignLB | BenignB | Sum |
---|---|---|---|---|---|---|
synonymous | 8 | |||||
missense | 111 | 115 | ||||
nonsense | 3 | |||||
start loss | 1 | 1 | ||||
frameshift | 4 | |||||
splice donor/acceptor (+/-2bp) | 1 | |||||
Total | 3 | 5 | 112 | 11 | 1 |
Highest pathogenic variant AF is 0.00000478839
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
UBE4A | protein_coding | protein_coding | ENST00000431736 | 19 | 39627 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.109 | 0.891 | 125727 | 0 | 17 | 125744 | 0.0000676 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 2.21 | 436 | 587 | 0.743 | 0.0000312 | 7149 |
Missense in Polyphen | 90 | 183.05 | 0.49168 | 2289 | ||
Synonymous | 1.35 | 180 | 205 | 0.880 | 0.00000984 | 1993 |
Loss of Function | 5.11 | 13 | 53.3 | 0.244 | 0.00000300 | 601 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000178 | 0.000178 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00 | 0.00 |
Finnish | 0.0000937 | 0.0000924 |
European (Non-Finnish) | 0.0000706 | 0.0000703 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.0000327 | 0.0000327 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Ubiquitin-protein ligase that probably functions as an E3 ligase in conjunction with specific E1 and E2 ligases. May also function as an E4 ligase mediating the assembly of polyubiquitin chains on substrates ubiquitinated by another E3 ubiquitin ligase. Mediates 'Lys-48'-linked polyubiquitination of substrates. {ECO:0000250|UniProtKB:E9Q735, ECO:0000250|UniProtKB:P54860}.;
- Pathway
- Ubiquitin mediated proteolysis - Homo sapiens (human);miR-targeted genes in epithelium - TarBase;miR-targeted genes in lymphocytes - TarBase;miR-targeted genes in muscle cell - TarBase;Immune System;Adaptive Immune System;Antigen processing: Ubiquitination & Proteasome degradation;Class I MHC mediated antigen processing & presentation
(Consensus)
Recessive Scores
- pRec
- 0.0990
Intolerance Scores
- loftool
- 0.600
- rvis_EVS
- -1.09
- rvis_percentile_EVS
- 7.15
Haploinsufficiency Scores
- pHI
- 0.206
- hipred
- Y
- hipred_score
- 0.639
- ghis
- 0.531
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.869
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Ube4a
- Phenotype
Gene ontology
- Biological process
- protein polyubiquitination;ubiquitin-dependent protein catabolic process;ubiquitin-dependent ERAD pathway
- Cellular component
- ubiquitin ligase complex;nucleus;cytoplasm
- Molecular function
- protein binding;ubiquitin-ubiquitin ligase activity